90
Participants
Start Date
May 25, 2012
Primary Completion Date
October 28, 2019
Study Completion Date
October 28, 2019
Peginterferon alfa-2a
180 μg per week s.c. for a total duration of 48 weeks.
Nucleos(t)ide analogue
All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
Toronto General Hospital, Toronto
Erasmus Medical Center, Rotterdam
Onze Lieve Vrouwen Gasthuis, Amsterdam
VU university medical center, Amsterdam
Rijnstate Hospital, Arnhem
Reinier de Graaf Gasthuis, Delft
Spaarne Gasthuis, Haarlem
University Medical Center Utrecht, Utrecht
Lead Sponsor
Hoffmann-La Roche
INDUSTRY
Foundation for Liver Research
OTHER